Skip to main content
MedPathMedPath Home
Clinical Trials/IRCT20180125038507N1
IRCT20180125038507N1
Completed
Phase 3

Study of the therapeutic effects of Atomoxetine in comparison with placebo on reducing the incidence of symptoms in patients with recurrent vasovagal syncope;

Tehran University of Medical Sciences0 sites50 target enrollmentTBD
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
Not specified
Sponsor
Tehran University of Medical Sciences
Enrollment
50
Status
Completed
Last Updated
6 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
6 years ago
Study Type
Interventional
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • •Patients who come to the Tehran Heart Center with a complaint of syncope or pre\-syncope with the clinical diagnosis of vasovagal syncope or have undergone tilt test, if needed, and experienced at least 3 syncopal episodes in the past 3 months.

Exclusion Criteria

  • •Age under 10 or over 70 years old
  • •History of uncontrolled blood pressure
  • •History of structural heart disease
  • •History of epilepsy
  • •History of closed angle glaucoma
  • •History of diabetes mellitus
  • •History of coronary artery disease
  • •Ejection fraction \< 50%
  • •Use of monoamine oxidase inhibitors (MAOIs)
  • •Use of selective serotonin reuptake inhibitors (SSRIs)

Outcomes

Primary Outcomes

Not specified

Similar Trials

Recruiting
Phase 2
Study of the effect of Atomoxetine on cognitive symptoms in patients with schizophrenia
IRCT20101130005280N31Mashhad University of Medical Sciences42
Active, not recruiting
Not Applicable
An Open-Label Study of the Efficacy of Atomoxetine Hydrochloride on Quality of Life of Children and Adolescents with Attention-Deficit/Hyperactivity Disorder with or without comorbid conditions - NDChild or adolescent patients with Attention-Deficit/ Hyperactivity Disorder ADHDMedDRA version: 6.1Level: PTClassification code 10003736
EUCTR2005-005701-32-ITELI LILLY300
Not yet recruiting
Phase 3
Atomoxetine for cognitive impairment in Behcet's disease
IRCT20211206053288N1Tehran University of Medical Sciences40
Active, not recruiting
Phase 1
Evaluation of the effect of Atomoxetine on impulsive state of High impulsive Tourette’s patients.
EUCTR2019-004455-36-FRCHU DE POITIERS45
Recruiting
Phase 3
Evaluation of Atomoxetine efficacy on Freezing of gait in patient with ParkinsoParkinson disease.Secondary parkinsonism, unspecifiedG21.9
IRCT20211008052695N1Ahvaz University of Medical Sciences32